FDA and Health Canada Approve Thermedical’s Degassed Salineto Help Reduce Risk of Stroke

MONTREAL and WALTHAM, Mass., June16, 2020–The Montreal Heart Institute(MHI) and Thermedical®, a developer of thermal-ablation systemsto treat ventricular arrhythmias, today announced the first ablation performed using the groundbreaking Durablate® retractable needle catheter and degassed saline, which together eliminateover98% of the air bubbles that can lead to stroke. Health Canada and the U.S. Food & Drug Administration (FDA) approved Thermedical’s degassed saline for usewith itsSaline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter,currently being studiedfor the treatment of ventricular tachycardia(VT), a leading cause of sudden cardiac death worldwide.